Sucampo Pharmaceuticals Inc. Class A

SUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Sucampo Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty

WILMINGTON, Del.--(BUSINESS WIRE)--

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Sucampo Pharmaceuticals, Inc. (NASDAQGM: SCMP) (“Sucampo Pharmaceuticals” or the “Company”).

If you currently own shares of Sucampo Pharmaceuticals and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/sucampo-pharmaceuticals-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.

Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.

EN
22/01/2018

Underlying

Sucampo Pharmaceuticals Inc. Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sucampo Pharmaceuticals Inc. Class A

 PRESS RELEASE
Free
Sucampo Pharmac...

SUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springe...

WILMINGTON, Del.--(BUSINESS WIRE)-- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Sucampo Pharmaceuticals, Inc. (NASDAQGM: SCMP) (“Sucampo Pharmaceuticals” or the “Company”). If you currently own shares of Sucampo Pharmaceuticals and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigatio...

January 22, 2018 1 EN
 PRESS RELEASE
Free
Sucampo Pharmac...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Inves...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sucampo Pharmaceuticals, Inc. (“Sucampo” or the “Company”) (NASDAQ GM: SCMP) stock prior to December 27, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE: MNK) for $18.00 in cash per share of Sucampo stock. To learn more about the action and your rights, go to: ...

January 3, 2018 1 EN
 PRESS RELEASE
Free
Sucampo Pharmac...

SUCAMPO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney W...

DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) concerning the sale to Mallinckrodt plc. Under the terms of the agreement, Sucampo shareholders will only receive $18.00 in cash for each share owned, which is virtually no premium over the 52-week high and lower than at least one analyst’s estimated value of $43.00 per share. If you are an affected...

December 29, 2017 1 EN
 PRESS RELEASE
Free
Sucampo Pharmac...

CORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notif...

NEW YORK--(BUSINESS WIRE)-- Third paragraph, first sentence of release should read: You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE: MNK) for $18.00 in cash per share of Sucampo stock (instead of ... $28.00 in cash per share of Sucampo stock). The corrected release reads: INVESTOR ALERT: LEVI & KORSINSKY, LLP NOTIFIES INVESTORS OF AN INVESTIGATION CONCERNING WHETHER THE SALE OF SUCAMPO PHARMACEUTICALS, INC. TO ...

December 28, 2017 1 EN
 PRESS RELEASE
Free
Sucampo Pharmac...

SUCAMPO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Sucampo Pharmaceuticals, Inc. (NASDAQ GM: SCMP)? Did you purchase any of your shares prior to December 26, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Sucampo Pharmaceuticals, Inc. (“Sucampo” or the “Company”) (NASDAQ ...

December 27, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch